View Older Stories View More Recent Stories

Jun 3, 2022 08:00AM Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
Jun 3, 2022 08:00AM Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
May 31, 2022 08:00AM Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference
May 24, 2022 07:30AM Zai Lab Announces Upcoming Presentations at June Investor Conferences
May 20, 2022 04:01PM Zai Lab Announces Change to Virtual 2022 Annual General Meeting of Shareholders to be Held on June 22, 2022
May 10, 2022 04:01PM Zai Lab Announces First Quarter 2022 Financial Results and Corporate Updates
May 5, 2022 11:56AM Zai Lab Limited (ZLAB) Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART in Adults with Primary Immune Thrombocytopenia
May 5, 2022 11:54AM Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
Apr 28, 2022 07:30AM Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Apr 28, 2022 07:30AM Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
Apr 21, 2022 07:30AM Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm
Apr 20, 2022 07:30AM Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022
Apr 19, 2022 08:00AM Zai Lab Plants a Tree for Every Employee on Earth Day 2022
Apr 6, 2022 08:01AM Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting
Mar 23, 2022 07:30AM Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on March 28, 2022
Mar 20, 2022 08:00PM Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting
Mar 15, 2022 07:30AM Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer
Mar 1, 2022 04:05PM Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021
Feb 17, 2022 07:30AM Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China
Feb 15, 2022 07:30AM Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022
Feb 7, 2022 07:30AM Zai Lab Announces Upcoming Presentation at February Investor Conference
Jan 12, 2022 07:30AM Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer
Jan 6, 2022 07:36AM Zai Lab Limited (ZLAB) Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA
Jan 6, 2022 07:30AM Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA
Dec 29, 2021 07:30AM Zai Lab Announces Upcoming Presentations at January Investor Conferences
Dec 22, 2021 07:30AM Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
Dec 20, 2021 06:30AM Zai Lab (ZLAB) Partner argenx Announces FDA Approval of VYVGART in Generalized Myasthenia Gravis
Dec 17, 2021 06:09PM Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Dec 16, 2021 11:57AM Paratek Pharmaceuticals (PRTK) Partner Zai Lab (ZLAB) Gains China Approval for NUZYRA
Dec 16, 2021 11:36AM China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections 
Dec 16, 2021 04:43AM China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (AB
Dec 3, 2021 07:30AM Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
Nov 30, 2021 07:30AM Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian C
Nov 23, 2021 07:30AM Zai Lab Announces Upcoming Presentations at December Investor Conferences
Nov 22, 2021 07:30AM Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
Nov 16, 2021 07:30AM Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDP
Nov 15, 2021 07:30AM Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus
Nov 11, 2021 07:30AM Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia
Nov 9, 2021 04:10PM Zai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates
Nov 9, 2021 08:00AM Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
Nov 9, 2021 08:00AM Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
Nov 9, 2021 07:37AM PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
Nov 9, 2021 07:00AM Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
Nov 9, 2021 07:00AM Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
Nov 4, 2021 07:30AM Zai Lab Announces Upcoming Presentations in November Investor Conferences
Oct 26, 2021 07:30AM Zai Lab to Announce Third Quarter 2021 Financial Results
Oct 25, 2021 07:30AM Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab
Oct 20, 2021 04:05PM ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study
Oct 13, 2021 10:01AM Geneseeq and Zai Lab (ZLAB) Announce Strategic Collaboration to Advance Cancer Drug R&D
Oct 13, 2021 10:00AM Geneseeq and Zai Lab Announce Strategic Collaboration to Advance Cancer Drug R&D
View More Recent Stories View Older Stories